These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1023 related articles for article (PubMed ID: 8052972)

  • 1. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions.
    Zwaginga JJ; Koomans HA; Sixma JJ; Rabelink TJ
    J Clin Invest; 1994 Jan; 93(1):204-11. PubMed ID: 8282789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall--studies in a porcine model.
    Badimon L; Martínez-González J; Royo T; Lassila R; Badimon JJ
    Thromb Haemost; 1999 Dec; 82(6):1736-42. PubMed ID: 10613663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
    Hamada M; Sugimoto M; Matsui H; Mizuno T; Shida Y; Doi M; Fukushima H; Nishio K; Yoshioka A; Shima M
    Thromb Haemost; 2011 Feb; 105(2):313-20. PubMed ID: 21136018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated human blood.
    Salatti JA; Anton P; Nemerson Y; Sakariassen KS
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):881-90. PubMed ID: 8148480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HN-11500--a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions.
    Roald HE; Barstad RM; Engen A; Kierulf P; Skjørten F; Sakariassen KS
    Thromb Haemost; 1994 Jan; 71(1):103-9. PubMed ID: 8165627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor.
    Vilahur G; Pena E; Padró T; Badimon L
    Thromb Haemost; 2007 Apr; 97(4):650-7. PubMed ID: 17393029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation.
    Badimon L; Badimon JJ; Lassila R; Heras M; Chesebro JH; Fuster V
    Blood; 1991 Jul; 78(2):423-34. PubMed ID: 2070078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet recruitment to arterial lesions by predeposition of platelets containing encapsulated iloprost.
    Pfliegler G; el-Gamal B; Badimon JJ; Badimon L; Crawford N
    Thromb Haemost; 1994 Oct; 72(4):604-10. PubMed ID: 7533337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation].
    Pastorova VE; Liapina LA; Cherkasova KA; Ashmarin IP
    Usp Fiziol Nauk; 1999; 30(2):80-91. PubMed ID: 10420478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
    Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
    Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.